Guidance

Devices which incorporate an ancillary medicinal substance

Guidance for notified bodies: devices which incorporate an ancillary medicinal substance

From:
Medicines and Healthcare products Regulatory Agency
Published
13 May 2016
Last updated
6 October 2017 — See all updates

This publication was withdrawn on

This publication was withdrawn on 29 December 2020 This publication has been withdrawn as it is no longer applicable. EU Notified Bodies are not able to consult with MHRA under EU medical device legislation.

Documents

Withdrawn: Guidance for notified bodies: devices which incorporate an ancillary medicinal substance

PDF, 1.1 MB, 30 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This Guidance is for Notified Bodies and their client companies wishing to consult the Medicines and Healthcare products Regulatory Agency (MHRA) with regard to the ancillary medicinal substance incorporated in a medical device.

Published 13 May 2016
Last updated 6 October 2017 + show all updates

  1. Updated attachment

  2. First published.

Related content